151 related articles for article (PubMed ID: 34325089)
41. Pretargeted radioimmunotherapy and SPECT imaging of peritoneal carcinomatosis using bioorthogonal click chemistry: probe selection and first proof-of-concept.
Rondon A; Schmitt S; Briat A; Ty N; Maigne L; Quintana M; Membreno R; Zeglis BM; Navarro-Teulon I; Pouget JP; Chezal JM; Miot-Noirault E; Moreau E; Degoul F
Theranostics; 2019; 9(22):6706-6718. PubMed ID: 31588245
[No Abstract] [Full Text] [Related]
42. [Contrast media and renal function].
Lindgren L
Duodecim; 1996; 112(5):353-5. PubMed ID: 10592594
[No Abstract] [Full Text] [Related]
43. Somatostatin receptor targeting with hydrophilic [
Makris G; Kuchuk M; Gallazzi F; Jurisson SS; Smith CJ; Hennkens HM
Nucl Med Biol; 2019 Apr; 71():39-46. PubMed ID: 31129499
[TBL] [Abstract][Full Text] [Related]
44. SPECT Imaging of Hepatocellular Carcinoma Detection by the GPC3 Receptor.
Xu H; Tang Y; Zhao Y; Wang F; Gao X; Deng D; Gu Y
Mol Pharm; 2021 May; 18(5):2082-2090. PubMed ID: 33797932
[TBL] [Abstract][Full Text] [Related]
45. Imaging patients with kidney disease: how do we approach contrast-related toxicity?
Perazella MA; Reilly RF
Am J Med Sci; 2011 Mar; 341(3):215-21. PubMed ID: 21139495
[TBL] [Abstract][Full Text] [Related]
46. Tumor-to-Normal Ratio Relationship between Planning Technetium-99 Macroaggregated Albumin and Posttherapy Yttrium-90 Bremsstrahlung SPECT/CT.
Villalobos A; Cheng B; Wagstaff W; Sethi I; Bercu Z; Schuster DM; Brandon DC; Galt J; Kokabi N
J Vasc Interv Radiol; 2021 May; 32(5):752-760. PubMed ID: 33642158
[TBL] [Abstract][Full Text] [Related]
47. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
48. Melanoma Imaging Using
Zhang C; Zhang Z; Lin KS; Lau J; Zeisler J; Colpo N; Perrin DM; Bénard F
Mol Pharm; 2018 Jun; 15(6):2116-2122. PubMed ID: 29714486
[TBL] [Abstract][Full Text] [Related]
49. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
[TBL] [Abstract][Full Text] [Related]
50. MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy.
Wessels BW; Konijnenberg MW; Dale RG; Breitz HB; Cremonesi M; Meredith RF; Green AJ; Bouchet LG; Brill AB; Bolch WE; Sgouros G; Thomas SR
J Nucl Med; 2008 Nov; 49(11):1884-99. PubMed ID: 18927342
[TBL] [Abstract][Full Text] [Related]
51. In Vivo Labeling of Plasma Proteins for Imaging of Enhanced Vascular Permeability in the Lungs.
Schniering J; Borgna F; Siwowska K; Benešová M; Cohrs S; Hasler R; van der Meulen NP; Maurer B; Schibli R; Müller C
Mol Pharm; 2018 Nov; 15(11):4995-5004. PubMed ID: 30265552
[TBL] [Abstract][Full Text] [Related]
52. Exploring Structural Parameters for Pretargeting Radioligand Optimization.
Meyer JP; Kozlowski P; Jackson J; Cunanan KM; Adumeau P; Dilling TR; Zeglis BM; Lewis JS
J Med Chem; 2017 Oct; 60(19):8201-8217. PubMed ID: 28857566
[TBL] [Abstract][Full Text] [Related]
53. Development of
Potemkin R; Strauch B; Kuwert T; Prante O; Maschauer S
Mol Pharm; 2020 Mar; 17(3):933-943. PubMed ID: 32011889
[TBL] [Abstract][Full Text] [Related]
54. Nuclear imaging of prostate cancer with gastrin-releasing-peptide-receptor targeted radiopharmaceuticals.
Ananias HJ; de Jong IJ; Dierckx RA; van de Wiele C; Helfrich W; Elsinga PH
Curr Pharm Des; 2008; 14(28):3033-47. PubMed ID: 18991717
[TBL] [Abstract][Full Text] [Related]
55. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose.
Förster GJ; Santos EB; Smith-Jones PM; Zanzonico P; Larson SM
J Nucl Med; 2006 Jan; 47(1):140-9. PubMed ID: 16391198
[TBL] [Abstract][Full Text] [Related]
56. Tumour targeting with radiometals for diagnosis and therapy.
Ramogida CF; Orvig C
Chem Commun (Camb); 2013 May; 49(42):4720-39. PubMed ID: 23599005
[TBL] [Abstract][Full Text] [Related]
57. Labeling a TCO-functionalized single domain antibody fragment with
Zhou Z; Zalutsky MR; Vaidyanathan G
Bioorg Med Chem; 2020 Sep; 28(17):115634. PubMed ID: 32773089
[TBL] [Abstract][Full Text] [Related]
58. Tumor retention of 186Re-MAG3, 111In-DTPA and 125I labeled monoclonal antibody G250 in nude mice with renal cell carcinoma xenografts.
Steffens MG; Kranenborg MH; Boerman OC; Zegwaart-Hagemeier NE; Debruyne FM; Corstens FH; Oosterwijk E
Cancer Biother Radiopharm; 1998 Apr; 13(2):133-9. PubMed ID: 10850349
[TBL] [Abstract][Full Text] [Related]
59. Influence of Several Compounds and Drugs on the Renal Uptake of Radiolabeled Affibody Molecules.
Garousi J; Vorobyeva A; Altai M
Molecules; 2020 Jun; 25(11):. PubMed ID: 32526905
[TBL] [Abstract][Full Text] [Related]
60. Folate receptor-targeted radionuclide therapy: preclinical investigation of anti-tumor effects and potential radionephropathy.
Haller S; Reber J; Brandt S; Bernhardt P; Groehn V; Schibli R; Müller C
Nucl Med Biol; 2015 Oct; 42(10):770-9. PubMed ID: 26162583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]